Journal Article

Pharmacogenetics of Nevirapine-Associated Hepatotoxicity: An Adult AIDS Clinical Trials Group Collaboration

Wilkinson, Grant R., Bartlett, John A., Ingram, Christiana D., Andersen, Janet W., Lederman, Michael M., Sanne, Ian, Hinkle, John, Rousseau, Franck, Haas, David W., Shaw, Audrey, Kim, Richard B.

2006

Overview

Associations have been reported between an MDR1 variant and responses to nonnucleoside reverse-transcriptase inhibitors. We explored associations between MDR1, CYP2B6, and CYP3A polymorphisms and nevirapine hepatotoxicity. Among participants in a randomized study in South Africa (FTC-302), MDR1 3435C→;T was significantly associated with decreased risk of hepatotoxicity (risk ratio, 0.30; P = .016).

• Publisher: The University of Chicago Press,University of Chicago Press,Oxford University Press
• Subject: Acquired immune deficiency syndrome / Adult / AIDS / Alleles / Anti-HIV Agents - adverse effects / Anti-HIV Agents - metabolism / Anti-HIV Agents - therapeutic use / Aryl Hydrocarbon Hydroxylases - genetics / Case-Control Studies / Chemical and Drug Induced Liver Injury / Clinical trials / Cytochrome P-450 CYP2B6 / Cytochrome P-450 CYP3A / Cytochrome P-450 Enzyme System - genetics / Drug therapy / Female / Gene Frequency / Genes, MDR / Genotype / Grants / Haplotypes / Hepatotoxicity / HIV Infections - drug therapy / HIV-1 / HIV/AIDS / Humans / Liver - drug effects / Liver Diseases - genetics / Liver Diseases - virology / Male / Medical genetics / Medical specialists / Nevirapine - adverse effects / Nevirapine - metabolism / Nevirapine - therapeutic use / Oxidoreductases, N-Demethylating - genetics / Pharmacogenetics / Polymorphism / Polymorphism, Genetic / Randomized Controlled Trials as Topic / Reverse Transcriptase Inhibitors - adverse effects / Reverse Transcriptase Inhibitors - metabolism / Reverse Transcriptase Inhibitors - therapeutic use / Risk reduction / RNA / South Africa / Toxicity